Rizvi N, et al. Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial. Abstract OA04.07. WCLC 2019, 7-10 september, Barcelona, Spanje.
Epcoritamab en tislelizumab in de sluis geplaatst
nov 2023 | Lymfoom, Maag-darm-leveroncologie